Drug
At2101
At2101: highest development phase Phase 1, developed by Amicus Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Amicus Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| AT2101 NCT00875160 | Phase 1 | Type 1 Gaucher Disease |
Latest
No recent events.
Follow At2101 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.